- Home
- ADC vs BPMC Comparison
ADC vs BPMC Comparison
Compare ADC & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADC
- BPMC
- Stock Information
- Founded
- ADC 1971
- BPMC 2008
- Country
- ADC United States
- BPMC United States
- Employees
- ADC N/A
- BPMC N/A
- Industry
- ADC Real Estate Investment Trusts
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- ADC Real Estate
- BPMC Health Care
- Exchange
- ADC Nasdaq
- BPMC Nasdaq
- Market Cap
- ADC 8.5B
- BPMC 8.3B
- IPO Year
- ADC 1994
- BPMC 2015
- Fundamental
- Price
- ADC $71.26
- BPMC $128.40
- Analyst Decision
- ADC Buy
- BPMC Buy
- Analyst Count
- ADC 14
- BPMC 20
- Target Price
- ADC $80.65
- BPMC $127.82
- AVG Volume (30 Days)
- ADC 1.1M
- BPMC 3.5M
- Earning Date
- ADC 07-31-2025
- BPMC 07-31-2025
- Dividend Yield
- ADC 4.25%
- BPMC N/A
- EPS Growth
- ADC 4.57
- BPMC N/A
- EPS
- ADC 1.77
- BPMC N/A
- Revenue
- ADC $636,802,000.00
- BPMC $562,121,000.00
- Revenue This Year
- ADC $12.74
- BPMC $44.46
- Revenue Next Year
- ADC $10.64
- BPMC $32.78
- P/E Ratio
- ADC $40.36
- BPMC N/A
- Revenue Growth
- ADC 13.65
- BPMC 99.19
- 52 Week Low
- ADC $61.34
- BPMC $73.04
- 52 Week High
- ADC $79.65
- BPMC $128.75
- Technical
- Relative Strength Index (RSI)
- ADC 33.97
- BPMC 74.76
- Support Level
- ADC $71.01
- BPMC $128.06
- Resistance Level
- ADC $72.69
- BPMC $128.78
- Average True Range (ATR)
- ADC 1.17
- BPMC 0.26
- MACD
- ADC -0.25
- BPMC -1.13
- Stochastic Oscillator
- ADC 3.46
- BPMC 53.85
About ADC Agree Realty Corporation
Agree Realty Corporation operates as a fully integrated real estate investment trust mainly focused on the ownership, acquisition, development and management of retail properties net leased to industry-tenants. The Company is mainly in the business of acquiring, developing and managing retail real estate. Some of its properties in the portfolio include Walmart, 7-Eleven, Wawa, Gerber Collision and others.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.